However, in order to achieve this, it will be essential to overcome the current limitations of molecules targeting SRC-3 and to design/develop new nanocarrier systems that will enable the delivery of these molecules to specific cell types such as cancer stem cells (CSCs). This evidence concerns the gene NCOA3 and cancer.